Photo from wikipedia
A pediatric patient with Crohn’s disease refractory to anti-tumor necrosis factor therapy, vedolizumab, ustekinumab, and 6-mercaptopurine achieved rapid clinical remission with upadacitinib. This is the first report of successful use… Click to show full abstract
A pediatric patient with Crohn’s disease refractory to anti-tumor necrosis factor therapy, vedolizumab, ustekinumab, and 6-mercaptopurine achieved rapid clinical remission with upadacitinib. This is the first report of successful use of upadacitinib in pediatric inflammatory bowel disease.
Keywords:
clinical remission;
disease;
crohn disease;
pediatric patient;
rapid clinical;
remission upadacitinib
Journal Title: Inflammatory bowel diseases
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Inflammatory bowel diseases
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!